symptomatic management of bronchopleural fistula (BPF) or air-leak secondary to intrapulmonary or pleural-based neoplasm. Materials/Methods: A retrospective study completed at one institution evaluating patients with intrapulmonary/pleural neoplasms who were symptomatically managed with IBV. Endpoints of this study are resolution of BPF, subjective improvement of symptoms, durability of response/recurrent BPF, and safety of the procedure. Patients presented with symptoms of BPF either secondary to surgical resection or subsequent to disease. IBV were placed using endobronchial techniques. Patients were evaluated by age, sex, tumor histology, tumor stage, intrapulmonary location, prior therapy (chemotherapy, surgery, radiation), resolution of air leak symptoms, procedural complications, and duration of cytotoxic therapy following IBV placement. Results: Eleven patients, 6 male and 5 female, were included in this study, with 1 female having 2 separate instances of BPF/persistent air leak. A total of 25 IBV were placed among all patients. All patients were stage IV. Histology was nonesmall cell lung cancer (NSCLC)-adenocarcinoma (5 patients), NSCLCadenosquamous (1 patient), infiltrating ductal carcinoma of the breast (1 patient), adenocarcinoma of unknown primary (2 patients; 1 suspected pancreatic and 1 suspected colon), colon adenocarcinoma (1 patient), squamous cell carcinoma of the cervix (1 patient). Resolution of air leak symptoms occurred in all patients. No procedural complications, including bleeding, pneumothorax, acute respiratory failure, or death occurred. There was 1 patient where removal of valves was not possible due to tumor occlusion and necrosis. Nine patients were able to continue on cytotoxic therapy following IBV placement for a median duration of 6.46 months (95% CI +/-4.02), with 4 patients still undergoing therapy after a median 11.3 months (95% CI +/-6.11). Seven patients died and 2 patients did not receive cytotoxic therapy. Median survival of the 7 deceased patients from time of IBV placement was 6.16 months (95% CI +/-2.51). Conclusion: Multiple tumor histologies, dependent upon intrapulmonary location, may predispose patients to BPF and subsequent associated morbidity. IBV provides a safe and effective means of managing these patients while they continue with primary treatment of their neoplasms.